drugset / Trial / NCT00126321

Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)

NCT00126321

Phase 2 Unknown 50 enrolled University Hospital, Bonn
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and the efficacy of cladribine, high-dose cytarabine and idarubicin in the treatment of patients with relapsed acute myeloid leukemia.

Timeline

Start
2004-11
Primary completion
2010-11
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cladribine Small molecule